Brentuximab vedotin, an antibody–drug conjugate targeting CD30, was evaluated in patients with chemotherapy-refractory tumors with an embryonal carcinoma component and expression of CD30 [157]. This evidence concerns the gene TNFRSF8 and embryonal carcinoma.